滚动资讯
FierceBiotechMcKesson swaps minority stake in surgical unit to Apollo Funds for $1.25BFierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industryFierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1BThermo FisherGlobal Cloud ELN Service Market | USA, China, India Lead | Thermo Fisher Scientific, Agilent Technologies, Dassault Systèmes Drive Digital Lab Transformation - PR NewswireAgilentAgilent’s Expanding Role in Advanced Therapeutics - Contract PharmaBioWorldAI opens the way to systematic risk assessment of zoonotic potential of virusesBioWorldSingularity Pharma discloses new mitragynine analoguesBioWorldJiangsu Vcare Pharmatech identifies new IL-17A inhibitorsBioWorldRuijin Hospital and Shanghai Jiao Tong University discover GSPT1 degradation inducersAgilentAgilent Technologies (A) Launches Key Cancer Diagnostic Tool - GuruFocusFierceBiotech诺华在抗凝药三期试验中未能超越艾乐妥后，调整研发重点。
eLife 2025年11月28日

<i>Shigella flexneri</i>效应蛋白IpaH1.4促进RNF213降解并保护胞质细菌免受干扰素诱导的泛素化作用

Shigella flexneri 效应蛋白IpaH1.4促进RNF213降解并保护胞质细菌免受干扰素诱导的泛素化作用

原文
暂时没有全文，请查看原始来源。